Intrinsiqq
Sabra Health Care REIT, Inc. logoSabra Health Care REIT, Inc.SBRA
$18.90-2.68%
Sabra Health Care REIT, Inc. logo

Sabra Health Care REIT, Inc.

SBRA

$18.90

-$0.52 (-2.68%)

⊜ Compare
ProfitabilityN/AGrowthSteady growthCash FlowN/AValuationRichly valued
What's changing

Revenue grew 10.2%, still solid.

What deserves caution

At 73x earnings, the current multiple leaves limited room for execution misses or growth deceleration.

Valuation context

72.7x earnings. The market is pricing in years of above-average growth. If that thesis breaks, downside from multiple compression alone could be 30%+. This is a stock where you're paying for the future, not the present.

Price History

+4.4%

Valuation & Multiples

Based on TTM earnings · Diluted shares

Market Cap$4.83B
EPS$0.26
P/E72.69
P/FCF—
EV/EBITDA—
FCF Yield—
Div. Yield6.17%
Net Debt/FCF—
52-Week Range
$17.23$22.39

Profitability & Returns

Revenue (TTM)

$858M

▲ +10.2% YoY

Net Income (TTM)

$65M

▲ +22.8% YoY

Op. Margin

—

ROIC

—

Cash Flow & Balance Sheet

FCF

N/A

Op. Cash Flow (TTM)

$372M

▲ +12.3% YoY

Net Debt

$2.40B

Cash & Equiv.

$232M

5Y CAGR: +5.3%

Continue Research

SourceComputed from the 10-Q filed 27 Jul 2026, covering the period ending 30 Jun 2026, as reported to the SEC. Data last refreshed 12 Oct 2026. How this is calculated.

Price from market data, last close as of 21 Oct 2026. Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically.

Is Sabra Health Care REIT (SBRA) overvalued?

At a P/E of 72.7, Sabra Health Care REIT (SBRA)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.

On quality, Sabra Health Care REIT scores 54/100 on Intrinsiqq's quality scorecard (a mixed business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. It currently yields about 6.2%; see dividend safety for coverage and history. All figures are computed from SEC filings; read the full methodology, or see how the market compares in our US profitability statistics. This is analysis, not investment advice.

Frequently asked

Is Sabra Health Care REIT a high-quality business?+

Sabra Health Care REIT scores 54 out of 100 on Intrinsiqq's quality score, a weighted blend of 7 metrics each scored 0 to 100, which makes it a mixed business on these measures. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.

Does Sabra Health Care REIT (SBRA) pay a dividend, and how much?+

Yes, Sabra Health Care REIT pays a regular dividend of about $1.18 per share per year (typically in quarterly installments), a yield of roughly 6.2% at the current price. That is a payout ratio of about 455.5% of earnings, so the dividend is stretched at this level. Sabra Health Care REIT has grown the dividend at roughly 2.4% a year over the past few years. A low headline yield is not the same as a weak dividend: what matters is how well earnings and free cash flow cover the payout and whether it is growing, not the percentage alone. For SBRA's full payout history, growth streak and dividend-safety score, see the dividends tab.

Is Sabra Health Care REIT a good stock to buy right now?+

That depends on valuation and quality together, not either alone. you should weigh SBRA's valuation and scores 54/100 on quality (mixed). It also yields about 6.2%. A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.

Related stocks: Real Estate Investment Trusts

Spot a number that looks wrong? Check it in SBRA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing SBRA

Create a free account and get 14 days of Premium: every stock and every tool.

  • Unlimited stocks
  • Stock screener
  • Portfolio tracker
  • Editable DCF
  • Compare side by side
  • Unlimited alerts

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

SectorsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.